Reports Q1 revenue $25.4M, consensus $18.88M. “We made significant progress with our strategic plans to refocus our organizational efforts in the outpatient oncology community where PEDMARK use has been endorsed by the NCCN in the adolescent and young adult population. Effective April 1, CMS has amended our permanent J-code to specify the non-interchangeability of PEDMARK with other formulations of sodium thiosulfate. With the successful execution of the Norgine EU licensing agreement, we are well funded and confident in the significant market opportunity in front of us,” said Rosty Raykov, CEO of Fennec Pharmaceuticals.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FENC:
- Fennec Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
- FENC Upcoming Earnings Report: What to Expect?
- Fennec Pharmaceuticals to Report First Quarter 2024 Financial Results on May 14, 2024
- Fennec price target raised to $18 from $17 at H.C. Wainwright
- Fennec Pharmaceuticals Reports Strong 2023 Growth